Setonix Pharmaceuticals has described peroxisome proliferator-activated receptor Ī³ (PPARĪ³) modulators reported to be useful for the treatment of inflammatory disorders, metabolic syndrome, obesity, ...
The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback